Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110209 · ClinicalTrials.gov registry record
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
A clinical trial of Age-related Macular Degeneration (AMD), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 331,541
- Enrollment target
- 1
- Study location
NCT05110209: Completed study of Age-related Macular Degeneration (AMD), sponsored by Novartis Pharmaceuticals.
NCT05110209 is a study of Age-related Macular Degeneration (AMD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 331,541 participants, above the 54,559-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (508% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05110209, a study of Age-related Macular Degeneration (AMD), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 331,541 participants
- Enrollment target
- 1
- Study location
Study Summary
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.
Primary Outcome
Period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019 was assessed.
Conditions Studied
Interventions
- OTHER Aflibercept
- OTHER Ranibizumab
- OTHER Bevacizumab
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331,541 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2020-11-20 |
What the finished NCT05110209 record still lists
NCT05110209 is an observational study that tracks outcomes without assigning an intervention. Its 331,541 participants enrollment target places it among the larger protocols in the corpus, above the 54,559-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (508% higher).
The record links to 1 condition, with Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 3 interventions - of which Aflibercept is the first listed.
NCT05110209 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05110209 about?
NCT05110209 is a clinical study titled "Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)". In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 0...
What is the current status of trial NCT05110209?
This trial is currently completed. The enrollment target is 331,541 participants. The study started on 2020-07-15. Estimated completion is 2020-11-20.
What conditions does trial NCT05110209 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration (AMD).
What interventions are being tested in trial NCT05110209?
The interventions under investigation include: Aflibercept (OTHER), Ranibizumab (OTHER), Bevacizumab (OTHER).
Who is sponsoring clinical trial NCT05110209?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05110209 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration (AMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
RECRUITING
-
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RECRUITING · Phase 2
-
Active AMD Study to Improve Function in Veterans
RECRUITING · NA
-
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
COMPLETED
-
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI